Medicare’s latest prescription drug price cuts expose the failures of past leftist policies and spotlight how conservative leadership is reshaping the battle for affordable health care.
Story Highlights
- Medicare announces new price cuts for 15 high-cost drugs, including Ozempic and Wegovy, set to take effect in 2027.
- These reductions follow a government negotiation program launched by the Biden administration, but Trump’s separate deal with drugmakers achieved even lower prices for key medications.
- Critics argue the government negotiation program is less effective and risks limiting patient choice if drugmakers withdraw from Medicare.
- Price cuts are projected to save taxpayers $12 billion and Medicare enrollees $685 million in 2027, but questions remain about the sustainability and fairness of federal intervention.
Medicare’s Second Round of Drug Price Cuts: What’s New?
The Centers for Medicare and Medicaid Services announced on November 25, 2025, that the agency will lower prices on 15 costly prescription drugs under Medicare, featuring widely used medications such as Ozempic and Wegovy. The price reductions are part of the Medicare drug price negotiation program created under the Inflation Reduction Act, signed into law by former President Biden in 2022. Unlike earlier approaches, this program gives government negotiators authority to set what Medicare pays for certain drugs, with negotiated prices taking effect in 2027. The Biden-era program is now in its second round, following a 2024 deal on 10 other drugs.
Trump’s “Most Favored Nation” Approach: Lower Prices, Less Overreach
President Trump’s approach to prescription drug pricing stands in sharp contrast to the Biden administration’s negotiation program. Trump’s “most favored nation” policy relies on executive orders and voluntary deals directly with pharmaceutical companies, bypassing heavy-handed legislative intervention. Notably, Trump recently announced a deal with Novo Nordisk—the maker of Ozempic and Wegovy—that secured a $250 price for these drugs, undercutting the $274 price reached by the government negotiation program. Conservative critics argue that Trump’s method respects free-market principles and the constitutional limits on government power, while still delivering significant savings to American seniors.
Taxpayer Savings and Patient Concerns
The government estimates these new drug price cuts will save taxpayers $12 billion and Medicare enrollees $685 million in out-of-pocket costs in 2027. For example, the negotiated price for Ozempic, Rybelsus, and Wegovy drops to $274 for a 30-day supply, compared to a previous $959 list price. Other drugs, such as asthma treatment Trelegy Ellipta and prostate cancer drug Xtandi, also see dramatic reductions. However, these savings come with risks: drugmakers can refuse to accept negotiated prices, potentially withdrawing vital medications from Medicare coverage—a move that could restrict access for millions of seniors who rely on these treatments.
Limitations of Government Negotiation and the Threat to Patient Choice
While supporters of the negotiation program claim it will provide relief for taxpayers and beneficiaries, critics highlight significant concerns. The government’s aggressive negotiating stance may force drugmakers to exit the Medicare market if they refuse the deals, reducing choices for patients. Industry lawsuits have so far failed to overturn the program, but challenges continue. Analysts point out that the $274 negotiated price for Ozempic and Wegovy is still higher than Trump’s $250 deal, raising questions about the true efficiency of the government’s approach. As one health policy expert noted, Medicare beneficiaries and taxpayers could have secured better savings with the Trump-negotiated price.
Prescription Drug Affordability: The Ongoing Crisis
The high cost of prescription drugs remains a top concern for Americans, with surveys showing that one in five adults have skipped a prescription due to expense, and one in seven have cut pills or skipped doses to make their medications last longer. While the Medicare price negotiation program aims to address this, conservatives worry that heavy government intervention could backfire—eroding patient choice, undermining innovation, and threatening the principles of limited government. As the debate continues, the Trump administration’s focus on voluntary deals and tariff relief stands as an alternative that prioritizes both affordability and constitutional values.
